FDA approves Novartis’s multiple myeloma drug Farydak
Farydak is the first histone deacetylase (HDAC) inhibitor approved in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication, to treat patients who received at